Africa Results News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Gold Fields: Solid Gold Miner, Excellent Balance Sheet, And A Great Price

Gold Fields: Solid Gold Miner, Excellent Balance Sheet, And A Great Price
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

South africaNew south walesGold fieldsGhana generalCerro coronaSouth africanSalares norteBarrick goldCompany financialsConstruction workers inspectingSouth deepHits mexicanEndeavour miningWest africanSouth deep mineCerro corona mine

Novavax COVID-19 Vaccine Demonstrates 89 3% Efficacy in UK Phase 3 Trial

Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial January 28, 2021 16:05 ET | Source: Novavax, Inc. Novavax, Inc. First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants Strong efficacy in Phase 3 UK trial with over 50% of cases attributable to the now-predominant UK variant and the remainder attributable to COVID-19 virus Clinical efficacy demonstrated in Phase 2b South Africa trial with over 90% of sequenced cases attributable to prevalent South Africa escape variant Company to host investor conference call today at 4:30pm ET GAITHERSBURG, Md., Jan. 28, 2021 (GLOBE NEWSWIRE) Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3%, in its Phase 3 clinical trial conducted in the

United kingdomSouth africaSouth africansEdna kaplanErika trahan schultzGregorym glennStanleyc erckClive dixJennifer porcelliNational institute of allergyDepartment of defenseMelinda gates foundationCoalition for epidemic preparedness innovationsNovavax incInfectious diseases analytics research unitInvestors novavax inc

Investegate |Novavax, Inc Announcements | Novavax, Inc : Novavax COVID-19 Vaccine Demonstrates 89 3% Efficacy in UK Phase 3 Trial

Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants Strong efficacy in Phase 3 UK trial with over 50% of cases attributable to the now-predominant UK variant and the remainder attributable to COVID-19 virus Clinical efficacy demonstrated in Phase 2b South Africa trial with over 90% of sequenced cases attributable to prevalent South Africa escape variant Company to host investor conference call today at 4:30pm ET GAITHERSBURG, Md., Jan. 28, 2021 (GLOBE NEWSWIRE) Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3%, in its Phase 3 clinical trial conducted in the United Kingdom (UK). The study assessed efficacy during a period with high transmission and with

United kingdomSouth africaSouth africansGregorym glennStanleyc erckClive dixInfectious diseases analytics research unitUs department of healthDepartment of defenseHuman servicesNational institutes of healthBiomedical advanced researchNational institute of allergyMelinda gates foundationDevelopment authorityCoalition for epidemic preparedness innovations